Vietnamese manufacturers looking at Europe usually ask about the dossier first. The facility question has to be answered earlier.
There are three realistic pathways, and they differ mostly in time and in where the risk sits.
- Acquire an existing marketing authorisation and transfer the manufacturing site. Often the fastest route to a product on the market, if a suitable MA is available. The work is a site transfer variation, comparability data and an EU GMP inspection of the Vietnamese site.
- New registration via technology transfer. A product developed elsewhere is transferred in, and a new dossier in CTD/eCTD format is built around the Vietnamese site's data.
- In-house development. Full control of the product and the data, and the longest timeline, with a complete dossier at the end.
Whatever the route, some things are common to all three: an EU GMP-compliant quality system and site, a marketing authorisation holder established in the EU, a Qualified Person to certify batches for release, and a pharmacovigilance system.
On the facility side, a plant designed and operated to WHO-GMP may need real changes to pass an EU inspection, particularly for sterile products under the 2022 Annex 1.
Our EU-GMP roadmap work covers QMS, dossier, technology transfer, MAH, QP and pharmacovigilance arrangements, alongside the facility engineering itself.
Industries




